Cancer treatment has transformed over the last 25 years. Since the first genetically targeted treatments emerged in the 1990s and immune checkpoint inhibitors in the 2010s, oncology has consistently overshadowed other therapy areas. Cancer tops the approved drugs roster, the number and combined value of R&D programs, dealmaking numbers and venture capital investment. Total cancer drug sales of $180bn in 2022 eclipsed other areas and will grow to over $340bn by 2028, according to Evaluate. That’s more than double the next-best placed category, neurology products.
What Next In Oncology?
Finding The Next Generation Of Cancer Mega-Blockbusters Is Challenging
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?
More from Innovation
• By
AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs.
• By
The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.
• By
Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.
• By
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.
More from In Vivo
• By
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.